New Potential Therapy to Treat Pulmonary Fibrosis in Systemic Sclerosis and COVID-19
source: pixabay.com

New Potential Therapy to Treat Pulmonary Fibrosis in Systemic Sclerosis and COVID-19

Pulmonary fibrosis is a condition that is caused by scarring of the lungs which can lead to shortness of breath and other respiratory issues. Some cases of COVID-19 have lead to…

Continue Reading New Potential Therapy to Treat Pulmonary Fibrosis in Systemic Sclerosis and COVID-19
ACE-1334 for SSc-ILD Granted Orphan Drug Designation
© Hannah Chartock

ACE-1334 for SSc-ILD Granted Orphan Drug Designation

  Recently, biopharmaceutical company Acceleron Pharma Inc. ("Acceleron") announced that its investigational therapy ACE-1334 was granted Orphan Drug designation by the FDA. The treatment is designed for patients with systemic…

Continue Reading ACE-1334 for SSc-ILD Granted Orphan Drug Designation
Phase 3 Clinical Trial for Systemic Scleroderma Resumes Recruiting Patients
source: pixabay.com

Phase 3 Clinical Trial for Systemic Scleroderma Resumes Recruiting Patients

According to a story from PR Newswire, the drug company CiVi Biopharma, Inc. today announced that its subsidiary Eicos Sciences, Inc. has resumed recruiting patients for its phase 3 clinical…

Continue Reading Phase 3 Clinical Trial for Systemic Scleroderma Resumes Recruiting Patients
June is Scleroderma Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

June is Scleroderma Awareness Month: Spreading Rare Disease Awareness

According to a story from Scleroderma News, June is recognized as Scleroderma Awareness Month. While physical distancing as a result of the ongoing coronavirus/COVID-19 pandemic may keep some folks at…

Continue Reading June is Scleroderma Awareness Month: Spreading Rare Disease Awareness
Scleroderma Symptoms Shown to Be Alleviated with Tracleer Treatment
source: pixabay.com

Scleroderma Symptoms Shown to Be Alleviated with Tracleer Treatment

by Danielle Bradshaw from In The Cloud Copy A year-long study has shown that Tracleer greatly reduces the skin-related symptoms of scleroderma. The results also showed that although it helped…

Continue Reading Scleroderma Symptoms Shown to Be Alleviated with Tracleer Treatment
Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Pexels / Pixabay

Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis

  A news release from Benzinga shares that biotechnology company Emerald Health Pharmaceuticals is beginning a Phase 2 clinical study on EHP-101 as a treatment for patients with systemic sclerosis.…

Continue Reading Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension
source: pixabay.com

Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension

According to a story from Pulmonary Hypertension News, the results of a recent phase 3 clinical trial have determined that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) stand…

Continue Reading Two Part Treatment Proven Superior for Pulmonary Arterial Hypertension
ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
Specific Autoantibodies Linked to Scleroderma, Research Study Finds
source: pixabay.com

Specific Autoantibodies Linked to Scleroderma, Research Study Finds

By Jodee Redmond from In The Cloud Copy A recent study suggests that certain antibodies could be linked to specific human leukocyte antigen (HLA) genes and environmental components in scleroderma.…

Continue Reading Specific Autoantibodies Linked to Scleroderma, Research Study Finds
PRIVIGEN Earns Orphan Drug Designation as a Treatment for Scleroderma
source: pixabay.com

PRIVIGEN Earns Orphan Drug Designation as a Treatment for Scleroderma

According to a story from Benzinga, the biotherapeutics company CSL Behring has recently announced that its medical product PRIVIGEN ® has earned Orphan Drug designation from the US Food and…

Continue Reading PRIVIGEN Earns Orphan Drug Designation as a Treatment for Scleroderma
Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
source: pixabay.com

Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

According to a story from Pulmonary Hypertension News, a recent study has determined that cardiopulmonary exercise testing can be an effective method to help identify systemic sclerosis patients that are…

Continue Reading Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
source: pixabay.com

Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status

According to a publication from Scleroderma News, the American Food and Drug Administration (FDA) recently granted Breakthrough Therapy status to Ofev (generic name nintedanib), as a treatment for progressive fibrosing…

Continue Reading Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
PhotoLizM / Pixabay

Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins

According to a recent press release from XBiotech, a Texas-based biotechnology company, patient dosing is now underway in a phase 1 clinical study of the Company's investigational systemic sclerosis treatment, bermekimab.…

Continue Reading Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
Findings From a Mouse Study Could Have Major Implications for Scleroderma
jarleeknes / Pixabay

Findings From a Mouse Study Could Have Major Implications for Scleroderma

According to a story from Scleroderma News, the results of a recent mouse study could have significant implications for the future of scleroderma treatment. In the study, scientists used a…

Continue Reading Findings From a Mouse Study Could Have Major Implications for Scleroderma
ICYMI: New Treatment for Scleroderma Lung Disease Approved by the FDA
Pexels / Pixabay

ICYMI: New Treatment for Scleroderma Lung Disease Approved by the FDA

According to a story from American Nurse Today, the US Food and Drug Administration (FDA) approved a treatment on September 6th, 2019 for interstitial lung disease associated with scleroderma, a…

Continue Reading ICYMI: New Treatment for Scleroderma Lung Disease Approved by the FDA
Study to Investigate the Development of Lung Disease in Connective Tissue Disorders
felixioncool / Pixabay

Study to Investigate the Development of Lung Disease in Connective Tissue Disorders

A study record from clinicaltrials.gov is investigating the appearance of lung problems in patients with disorders affecting connective tissue. While prior research has documented the appearance of interstitial lung disease…

Continue Reading Study to Investigate the Development of Lung Disease in Connective Tissue Disorders
Combined Clinics Improves Treatment for Autoimmune Diseases
Movidagrafica / Pixabay

Combined Clinics Improves Treatment for Autoimmune Diseases

According to a story from The Rheumatologist, evidence suggests that patients with rare diseases, such as autoimmune diseases, can benefit from visiting combined clinics, which are special medical centers in…

Continue Reading Combined Clinics Improves Treatment for Autoimmune Diseases
Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
TeroVesalainen / Pixabay

Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease

According to a story from finanzen.at, the drug nintedanib (marketed as Ofev) has officially been approved by the US Food and Drug Administration (FDA) as a treatment for interstitial lung…

Continue Reading Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
stevepb / Pixabay

First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug

According to a story from Financial Buzz, the drug developer Emerald Health Pharmaceuticals, Inc., recently announced that the company had completed a phase 1 clinical trial for its experimental drug…

Continue Reading First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia
jarmoluk / Pixabay

New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia

According to a publication from Scleroderma News, a recent study published in Rheumatology International suggests that the majority of systemic sclerosis patients experience sarcopenia as a result of their condition. Perhaps…

Continue Reading New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia